Transcept Aims To Refile Intermezzo Insomnia NDA With Highway Driving Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approved a resubmission plan for Transcept Pharmaceuticals' insomnia drug Intermezzo that involves new packaging to foil inadvertent re-dosing and a next-day highway driving study to satisfy concerns the agency raised in a "complete response" letter, the company said March 24. The filing is targeted for late in the fourth quarter